If you have been reading about blood-brain barrier and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Free peptide form |
| Molecular mass | About 751.9 Da | Calculated average mass |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form TKPRPGP |
| Structural basis | Tuftsin analogue | Extended version of a natural tetrapeptide |
| Development origin | Russian Academy of Sciences | Work carried out from the 1980s onward |
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
=== Catalysis === Organic cages act as nano reactors for catalytic transformations. The confined environment enhances reaction rates and selectivity through concentration effects in the cavity, specific orientation of reactants, stabilization of transition states, and control over product distribution. The well-defined cavity creates a unique microenvironment that can accelerate reactions and influence product selectivity. Asymmetric catalysis benefits from chiral cage environments, enabling stereoselective transformations. The catalytic activity can be tuned through modification of cage structure and functionalization of the cavity interior. Integration of catalytic sites within the cage framework allows for size-selective catalysis, where only appropriately sized substrates can access the active sites.
Metoprolol, sold under the brand names Lopressor and Toprol-XL among others, is a medication used to treat angina, high blood pressure and a number of conditions involving an abnormally fast heart rate. It is also used to prevent further heart problems after myocardial infarction and to prevent headaches in those with migraines. It is a beta blocker, specifically a selective competitive β1 receptor blocker, and is taken by mouth or is given intravenously. Common side effects include trouble sleeping, feeling tired, feeling faint, and abdominal discomfort. Large doses may cause serious toxicity. Risk in pregnancy has not been ruled out. It appears to be safe in breastfeeding. The metabolism of metoprolol can vary widely among patients, often as a result of hepatic impairment or CYP2D6 polymorphism. Metoprolol was first made in 1969, patented in 1970, and approved for medical use in 1978. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the sixth most commonly prescribed medication in the United States, with more than 59 million prescriptions.
28 September – Following a trial at the High Court in Stirling, Christopher McGowan, 28, is found guilty of the murder of Claire Inglis, his girlfriend who he battered and strangled, before burning her with a lighter and pushing a wet wipe down her throat. 29 September – Two Scottish postmasters convicted of embezzlement because of a faulty computer system have their convictions posthumously overturned by the Court of Criminal Appeal in Edinburgh. An office manager is awarded £37,000 by an industrial tribunal after her boss told her she used the menopause as an "excuse for everything". Two people are treated in hospital after a collision involving the Flying Scotsman locomotive and Royal Scotsman train at Aviemore railway station.
NH3 + 3 CH3CH2OH → N(CH2CH3)3 + 3 H2O The pKa of protonated triethylamine is 10.75, and it can be used to prepare buffer solutions at that pH. The hydrochloride salt, triethylamine hydrochloride (triethylammonium chloride [(CH3CH2)3NH]+Cl−), is a colorless, odorless, and hygroscopic powder, which decomposes when heated to 261 °C. Triethylamine is soluble in water to the extent of 112.4 g/L at 20 °C. It is also miscible in common organic solvents, such as acetone, ethanol, and diethyl ether. Laboratory samples of triethylamine can be purified by distilling from calcium hydride. In alkane solvents triethylamine is a Lewis base that forms adducts with a variety of Lewis acids, such as I2 and phenols. Owing to its steric bulk, it forms complexes with transition metals reluctantly.
The classic model for the enzyme-substrate interaction is the induced fit model. This model proposes that the initial interaction between enzyme and substrate is relatively weak, but that these weak interactions rapidly induce conformational changes in the enzyme that strengthen binding. The advantages of the induced fit mechanism arise due to the stabilizing effect of strong enzyme binding. There are two mechanisms of substrate binding: uniform binding, which has strong substrate binding, and differential binding, which has strong transition state binding. The stabilizing effect of uniform binding increases both substrate and transition state binding affinity, while differential binding increases only transition state binding affinity. Both are used by enzymes and have been evolutionarily chosen to minimize the activation energy of the reaction. Enzymes that are saturated, that is, have a high affinity substrate binding, require differential binding to reduce the energy of activation, whereas small substrate unbound enzymes may use either differential or uniform binding. These effects have led to most proteins using the differential binding mechanism to reduce the energy of activation, so most substrates have high affinity for the enzyme while in the transition state. Differential binding is carried out by the induced fit mechanism – the substrate first binds weakly, then the enzyme changes conformation increasing the affinity to the transition state and stabilizing it, so reducing the activation energy to reach it.
Sources: en.wikipedia.org
=== The ascending and descending method === This is the hybrid of both of the above techniques. The upper part of ascending chromatography can be folded over a rod in order to allow the paper to become descending after crossing the rod.
=== Pain phase === Classically, a migraine headache occurs on one side and throbs with moderate to severe intensity. The throbbing is not in phase with the person's pulse. In around 40% of cases, the pain may affect both sides of the head. The pain phase usually lasts 4 to 72 hours in adults. Children and young people more often have shorter headaches with pain on both sides. Pain is frequently accompanied by nausea, vomiting, sensitivity to light, sensitivity to sound, sensitivity to smells, fatigue, and irritability. Many prefer a dark and quiet environment and seek to avoid stimuli to which they are sensitive. Nausea has been reported by almost 90% of people who self-report with migraine, and vomiting has been reported in from 28% to 70% of patients. Other symptoms may include blurred vision, symptoms affecting the sinuses and nasal passages such as nasal stuffiness, diarrhea, neck pain, and swelling or tenderness of the scalp. In rare cases called migraine with brainstem aura, neurological symptoms such as a sense of the world spinning, light-headedness, and confusion may affect both sides of the body. During the pain phase, motion and physical activity may increase pain. Migraineurs are likely to decrease physical activity during this time. However, the effects of physical activity on migraine are complex. Regular moderate exercise may reduce the frequency of migraine attacks.
=== Economic value === In the areas in which it was endemic, the emu was an important source of meat to Aboriginal Australians. They used the fat as bush medicine and rubbed it into their skin. It served as a valuable lubricant, was used to oil wooden tools and utensils such as the coolamon, and was mixed with ochre to make the traditional paint for ceremonial body adornment. Their eggs were also foraged for food. An example of how the emu was cooked comes from the Arrernte of Central Australia who called it Kere ankerre:
=== Autism === An intranasal formulation of carbetocin was also under development for the treatment of autism, but development was discontinued as well. It was variously developed by Nastech Pharmaceutical Company, Retrophin (Travere Therapeutics), Marina Biotech, and Cypress Bioscience and had the developmental code name CYP-2001. The drug reached phase 1 trials for autism prior to being discontinued.
Sources: en.wikipedia.org
A cohort study indicates dietary intakes of total flavonols – and at least kaempferol- and quercetin-containing foods in specific – may substantially decrease decline in multiple cognitive abilities with older age, showing a difference of "0.4 units per decade" between 5 mg and 15 mg intakes. A paywalled study reports higher percentage of daily energy consumption of ultra-processed foods, such as white bread or instant noodles, was associated with faster cognitive decline in aging. Differences can be as large or larger than a 28% faster rate of global cognitive decline. Pharmaceutical/supplemental intervention-related results Researchers report that the widely used supplements glycine and NAC when combined as "GlyNAC", which previously showed various beneficial effects in humans i.a. in a small trial by the authors, can extend lifespan by 24% in mice when taken at old age. Biomedical gerontologists demonstrate a mechanism of anti-aging senolytics, in particular of Dasatinib plus Quercetin (D+Q) – an increase of α-Klotho as shown in mice, human cells and in a human trial. A study reports that in model animals, treatment with rapamycin – which typically has negative side-effects – for a limited timespan extended lifespan as much as life-long administration started at the same age and that it was most effective during early adulthood.
=== Modernity === Much research has pointed at the rising rates of depression, leading people to speculate that modernization may be a factor in the growing percentage of depressed people. One study found that women in urban America were much more likely to experience depression than those in rural Nigeria. Other studies have found a positive correlation between a country's GDP per capita, as quantitative measure of modernization, and lifetime risk of a mood disorder trended toward significance (p=0.06). Many people believe it is the increased number of pressures and expectations, increased isolation, increased individualism, and increased inactivity that contribute to higher rates of depression in modern societies.
Pathology Messaging Implementation Project (PMIP) is the project that introduced universal delivery of electronic pathology results to GPs in Great Britain. The resulting standard was formalised in 2003 as ISB 1557. It uses UN-EDIFACT based messages. More than 20 years later it remains extensively used by the British National Health Service (NHS) to transmit pathology orders and pathology test results. PMIP began in the United Kingdom as the PMEP (Pathology Messaging Enabling Project) under the control of the NHS Information Authority and was supported by the Royal College of Pathologists (Dr Rick Jones), the Royal College of GPs (Dr Stephen Pill) and the British Medical Association. PMIP was designed for the transmission of structured pathology orders and their associated results between pathology and primary care systems. The message definition followed the work on standardisation led by Dr Jonathan Kay and Dr John McVittie and was implemented in UN-EDIFACT as required at the time by the Department of Health. Originally messages were to be encrypted end-to-end (organisation-to-organisation) using public key infrastructure (PKI). The NHS subsequently moved to an alternative strategy using Data Transfer Service (DTS). Messages are encrypted from the pathology laboratory to the DTS server, and again from the DTS server to the General Practitioner using the PMIP interim messaging cryptographic service. The DTS provides application-to-application messaging within the NHS as well as providing a replacement for the X.400 service.
Sources: en.wikipedia.org
It is a seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, produced by chemical synthesis rather than extracted from biological tissue. Its design is based on tuftsin, a natural immunomodulatory tetrapeptide. The C-terminal Pro-Gly-Pro segment is a common stabilising motif in short regulatory peptides.
The core four residues correspond to tuftsin, which occurs naturally as part of immunoglobulin G. The full seven-residue sequence, however, is not a known endogenous peptide. It is a laboratory-designed analogue intended to combine tuftsin-like activity with greater resistance to breakdown.
No single receptor has been confirmed as the primary target. Reports describe involvement of the GABAergic system, interference with enkephalin degradation, and shifts in neurotrophic factor expression. Because these observations come from different models and assays, they have not yet been integrated into one accepted mechanism.
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.